Contributor Page
Arnold & Porter
 
Email  |  Website  |  Articles
Contact Details
Tel: +1 202 942.5000
Fax: +1 202 942.5999
601 Mass. Ave., NW
Washington, DC
DC 20001-3743
United States
By Robert Azarow, Kevin Toomey
In May, President Donald Trump signed into law the Economic Growth, Regulatory Relief, and Consumer Protection Act (the "Growth Act").
By Michael Gerrard, Edward McTiernan
In New York, the requirement that manufacturers disclose chemical ingredients contained in cleaning products can be traced ...
By Ian Dodds-Smith, Silvia Valverde
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) has recently published a new version of its Code of Practice ...
By Richard Alexander, Christopher Allen, David Freeman, Jr., Michael Mancusi, Brian McCormally, Erik Walsh, Kevin Toomey
On September 7, 2018, after considerable industry feedback and two issuances of temporary relief, the Financial Crimes Enforcement Network (FinCEN) ...
By Nathaniel Castellano, Charles Blanchard, Dominique Casimir
Palantir USG v. United States may prove to be one of the most significant procurement precedents of the decade. Affirming the Court of Federal Claims ...
By David Freeman, Jr., Christopher Allen, Robert Azarow, Michael Mancusi, Brian McCormally, Erik Walsh, Kevin Toomey
On September 11, 2018, the Board of Governors of the Federal Reserve System, Federal Deposit Insurance Corporation, National Credit Union Administration, Office of the Comptroller of the Currency, ...
By C. Scott Lent, Matthew Tabas, Amanda Croushore
US antitrust authorities and Congress have long been concerned with promoting competition in the pharmaceutical industry.
By Sean Curran, Kathleen Harris, Michael J. Atkinson, Maya Paunrana
Below we set out the key points of this judgment and their impact on corporate investigations.
By Sean Curran, Kathleen Harris, Michael J. Atkinson, Maya Paunrana
On Wednesday 5 September 2018, the Court of Appeal Civil Division delivered its judgment in the much-anticipated appeal of Director of the Serious Fraud Office v Eurasian Natural Resources Corporation [2018] EWCA Civ 2006.
By Daniel Kracov, Elizabeth Trentacost, Bryant M. Godfrey
The US Food & Drug Administration (FDA or the Agency) recently unveiled the next phase in the Agency's quest to implement a quality metrics program. On June 29, 2018,
By Rob Bratby
An exploration of international experiences and challenges ahead
By Bonnie Clemence, Jacqueline Mulryne
In July, we considered the implications of the UK Government's Brexit White paper, setting out its proposals for the UK's ongoing relationship with the EU post-Brexit ...
By Daisy Bray, Ewan Townsend
Data-driven technologies, particularly artificial intelligence and other complex algorithms, have the potential to enhance patient care and catalyse medical breakthroughs.
By Peter J. Schildkraut, Vernon G. Ross
oes your M&A due diligence checklist ask about FCC licenses? No? Well, the FCC just gave you a half million reasons to add a question—five hundred and four thousand, to be exact.
By Richard Alexander, Christopher Allen, David Freeman, Jr., Michael Mancusi, Brian McCormally, Erik Walsh, Kevin Toomey
On September 7, 2018, after considerable industry feedback and two issuances of temporary relief, the FinCEN issued permanent relief to the banking industry from the requirement to collect beneficial ownership,,,
Contributor's Topics
More...